Formulations and carrier systems including farnesylthiosalicylic moieties

A method of forming a formulation, comprising:

• forming a carrier agent by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, and
• associating a biologically active compound with the carrier agent.

A method of delivering a biologically active compound to a patient, comprising:

• delivering to the patient a composition comprising a carrier agent formed by conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist, wherein a plurality of the carrier agents are adapted to assemble into a structure and the at least one biologically active hydrophobic compound is conjugated with the at least one hydrophilic compound via a linkage which is labile in vivo, the composition further comprising a biologically active compound associated with the carrier agent.

A composition formed by:

• conjugating at least one biologically active hydrophobic compound with at least one hydrophilic compound via at least one linkage which is cleavable in vivo, the at least one biologically active hydrophobic compound selected from the group of farnesylthiosalicylic acid and a derivative of farnesylthiosalicylic acid which is biologically active as an RAS antagonist.